HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Qualifying Suppliers For US Supplement Ingredient Identity Requirement Still An Option With Thorns

Executive Summary

Failing to qualify suppliers “one of the more common citations” FDA inspectors find at supplement facilities, says ORA deputy director Michael Dutcher. “If you're not sort of reconfirming once in a while it could lead to a problem with your products that you weren't even expecting.”

You may also be interested in...



US FDA Supplement Facility Inspection Numbers Back To Typical Along With GMP Problems Found

Supplement facility GMP inspections by FDA in 2022 along with the frequency of form 483s sent to firms following inspections return to roughly pre-pandemic annual numbers after dipping during 2020 and 2021.

Warning Confirms Some Supplement GMP Violations Remain Common In US

An Oregon factory’s citations received by the FDA are among the most common violations the agency finds during inspections, ORA Office of Human and Animal Food Operations deputy director said.

Consumer Health Products Claiming Treatments For Moles, COVID-19 Back On US FDA Warning Radar

Product sold on Amazon among topical remedies for mole and skin tag removal back on US regulatory radar. Recent warnings show violative COVID-19 claims haven’t disappeared and supplement GMP problems remain common.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS152794

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel